Literature DB >> 10801237

Activation and control of self-reactive gammadelta T cells.

F Halary1, J J Fournié, M Bonneville.   

Abstract

Mammalian and avian CD3+ T cells can be separated into two lymphocyte subsets bearing heterodimeric T-cell receptors (TCR) composed of either alphabeta or gammadelta chains. Although it is now widely accepted that gammadelta and alphabeta T cells fulfill mandatory and nonredundant roles, the generality of this assumption and the exact functions played by gammadelta T cells remain uncertain. While an early protective role of gammadelta T cells has long been suspected, recent observations drawn in particular from transgenic models suggest their implication in the homeostatic control of immune and nonimmune processes. This hypothesis is also supported by the existence of several self-reactive gammadelta T-cell subsets in rodents and humans, whose specificity and effector properties will be detailed and discussed here. The present review will also describe several mechanisms that could allow efficient control of these self-reactive subsets while permitting expression of their regulatory and/or protective properties.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10801237     DOI: 10.1016/s1286-4579(99)80041-0

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  3 in total

1.  Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens.

Authors:  Andrew M Hebbeler; Cristiana Cairo; Jean Saville Cummings; C David Pauza
Journal:  Cancer Immunol Immunother       Date:  2006-11-28       Impact factor: 6.968

Review 2.  γδ T cell receptor ligands and modes of antigen recognition.

Authors:  Eric Champagne
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-02-06       Impact factor: 4.291

Review 3.  Human Vδ1+ T Cells in the Immune Response to Plasmodium falciparum Infection.

Authors:  Lars Hviid; Cecilia Smith-Togobo; Benjamin E Willcox
Journal:  Front Immunol       Date:  2019-02-14       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.